A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 05 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 27 May 2014 Planned number of patients changed from 30 to 65 as reported by ClinicalTrials.gov..
- 18 Oct 2013 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.